Hotbed/Location

Found 501,448 articles

• Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

  2/21/2019

  Ra Pharmaceuticals, Inc. announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New York Palace, New York, NY.

• Firmly on our way to becoming a fully integrated biopharma company

  2/21/2019

  FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability

• The Medicines Company Announces Upcoming Investor Conference Presentations

  2/21/2019

  The Medicines Company announced today that management will present company overviews at the following conferences

• Insilico and Teva enter collaboration to apply predictive Digital Twins for biopharmaceutical production

  2/21/2019

  Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.

• Exicure to Present at the 12th Annual European Life Sciences CEO Forum

  2/21/2019

  Exicure, Inc. announced that its CEO, Dr. David Giljohann, will present a corporate update at the 12th Annual European Life Sciences CEO Forum being held February 25-26, 2019 at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

• Denovo Biopharma Announces New Hires for Positions of Chief Medical Officer of Hematology and Senior Vice President, Regulatory Affairs and Quality Assurance

  2/21/2019

  Denovo Biopharma announced the hiring of two senior executives, reporting to the CEO: Lei Zhang, MD, as Chief Medical Officer, Hematology, and Bruce M. Wagman, as Senior Vice President, Regulatory Affairs and Quality Assurance.

• AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa

  2/21/2019

  AbbVie announced that they have received approval for an additional indication of HUMIRA, a fully human anti-TNF-alpha monoclonal antibody, for the treatment of hidradenitis suppurativa.

• Diagnostic Solutions Laboratory Revolutionizes Precision Medicine with GenomicInsight™ Genomic Health Profile Powered by Opus23 Explorer™

  2/21/2019

  Diagnostic Solutions Laboratory continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight™ Genomic Health Profile powered by Opus23 Explorer™

• Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

  2/21/2019

  DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients

• Terramera secures USD $10 million in financing from BDC

  2/21/2019

  Investment will help Vancouver-based cleantech firm commercialize technologies that promise to revolutionize agriculture

• Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

  2/21/2019

  Correvio Pharma Corp. announced that Correvio's management team will participate in 1-on-1 meetings at the 8th Annual SVB Leerink Healthcare Conference at the Lotte New York Palace on Thursday, February 28, 2019 in New York City.

• MorphoSys to Present at Upcoming Investor Conference

  2/21/2019

  MorphoSys AG will present at the following conference.

• ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

  2/21/2019

  ArQule, Inc. announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019.

• Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019

  2/21/2019

  Audentes Therapeutics, Inc., will host a conference call and webcast to report its fourth quarter and full year 2018 financial results and provide a corporate update on Wednesday, February 27, 2019.

• Recipharm AB publishes its report for the fourth quarter and full year 2018

  2/21/2019

  Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom

• Concert Pharmaceuticals to Report Full Year 2018 Results on February 28, 2019

  2/21/2019

  Concert Pharmaceuticals, Inc. announced that it will report its financial results for the year ended December 31, 2018, on Thursday, February 28, 2019, before the U.S. financial markets open.

• ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

  2/21/2019

  ArQule, Inc. announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City.

• Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

  2/21/2019

  Ardelyx, Inc. announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb. 28, 2019 at the Lotte New York Palace Hotel in New York City.

• DURECT Corporation to Participate in the Berenberg NASH Day

  2/21/2019

  DURECT Corporation today announced that James E. Brown, President and CEO, and Mike Arenberg, Chief Financial Officer, will be participating in the Berenberg NASH Day, taking place Tuesday, February 26, 2019, at Berenberg's New York City offices.

• Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results Conference Call

  2/21/2019

  Spectrum Pharmaceuticals, announced it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, February 28, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.